Multiple Myeloma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The multiple myeloma market reached a value of USD 19.2 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 46.1 Billion by 2036, exhibiting a growth rate (CAGR) of 8.30% during 2026-2036.

The multiple myeloma market has been comprehensively analyzed in IMARC’s new report titled “Multiple Myeloma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036”. Multiple myeloma is a cancer of the plasma cells. Plasma cells are white blood cells that make antibodies which protect against infection. Multiple myeloma involves an excessive growth of the cells crowding out normal cells in the bone marrow that produce red blood cells, platelets, and other white blood cells. Early on, patients having multiple myeloma might not notice any symptoms. But over time, they may develop common symptoms which include bone pain, weakness and fatigue, weight loss and loss of appetite, stomach problems, confusion, frequent infections, severe thirst, weakness or numbness in arms and legs, etc. Multiple myeloma can be hard to diagnose as it usually has few or no symptoms in the initial stages. Diagnosis for multiple myeloma may involve a range of blood tests, urine tests and bone or bone marrow tests. A number of these tests may also be used to assess the extent of the disease and to plan and monitor treatment.

One of the biggest drivers of the multiple myeloma market is the rising geriatric population. Since the incidence of multiple myeloma increases with age and rarely happens in people younger than 45 years of age, we expect a continuous growth in the global ageing population to create a positive impact on the multiple myeloma market. Furthermore, a rising prevalence of physical inactivity, overweight, obesity, and diabetes are also expected to drive this market as these factors are also associated with an increasing incidence and mortality of this indication. Multiple myeloma is now treated like a chronic disorder catalyzed by the rising efficiency and safety of currently available treatments. The cost of therapy for multiple myeloma, however, has become increasingly high as patients are living longer and use these treatments for extended periods of time. This cost burden on both payers and providers, however, will get some relief once generic versions for some of the key drugs are launched across the major markets.

IMARC Group's new report provides an exhaustive analysis of the multiple myeloma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for multiple myeloma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple myeloma market in any manner.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the multiple myeloma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the multiple myeloma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current multiple myeloma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the multiple myeloma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the multiple myeloma across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the multiple myeloma across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2020-2036) of multiple myeloma across the seven major markets?
• What is the number of incident cases (2020-2036) of multiple myeloma by age across the seven major markets?
• What is the number of incident cases (2020-2036) of multiple myeloma by gender across the seven major markets?
• What is the number of incident cases (2020-2036) of multiple myeloma by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with multiple myeloma across the seven major markets?
• What is the size of the multiple myeloma patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend multiple myeloma of?
• What will be the growth rate of patients across the seven major markets?

Multiple Myeloma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for multiple myeloma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple myeloma market?
• What are the key regulatory events related to the multiple myeloma market?
• What is the structure of clinical trial landscape by status related to the multiple myeloma market?
• What is the structure of clinical trial landscape by phase related to the multiple myeloma market?
• What is the structure of clinical trial landscape by route of administration related to the multiple myeloma market?